Teratogenic potential of valproic acid.
Valproic acid administration in pregnancy may be a potential teratogen to the developing fetus. Numerous animal studies have linked valproic acid to vertebral anomalies and renal agenesis. Recent European data have suggested valproic acid as a causal agent of neural tube defects in human offspring. Research relative to teratogenicity of valproic acid administration for petit mal epilepsy is reviewed. Conclusions indicate that the benefits of valproic acid administration outweigh the hazards of teratogenicity.
D000818:Animals; D004827:Epilepsy / Q000150:complications / Q000188:drug therapy; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008431:Maternal-Fetal Exchange; D009436:Neural Tube Defects / Q000139:chemically induced*; D009773:Obstetric Nursing; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy; D013723:Teratogens; D014635:Valproic Acid / Q000009:adverse effects*
D013723:Teratogens; D014635:Valproic Acid